166 related articles for article (PubMed ID: 37852032)
1. Discovery of highly potent and selective KRAS
Yang N; Fan Z; Sun S; Hu X; Mao Y; Jia C; Cai X; Xu T; Li B; Li Y; Han L; Wei T; Qian X; Qin W; Li P; Zheng Z; Li S
Eur J Med Chem; 2023 Dec; 261():115857. PubMed ID: 37852032
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of KRAS
Zhang X; Zhao T; Sun M; Li P; Lai M; Xie L; Chen J; Ding J; Xie H; Zhou J; Zhang H
Bioorg Med Chem; 2023 Jan; 78():117153. PubMed ID: 36621179
[TBL] [Abstract][Full Text] [Related]
3. Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity.
Li L; Wu Y; Yang Z; Xu C; Zhao H; Liu J; Chen J; Chen J
Bioorg Chem; 2021 Dec; 117():105447. PubMed ID: 34715575
[TBL] [Abstract][Full Text] [Related]
4. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS
Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB
Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128
[TBL] [Abstract][Full Text] [Related]
5. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
6. A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS
Lv Y; Yang Z; Chen Y; Ma X; Guo M; Zhang C; Jiang X; Wang C; Li Z; Tai Z; Wang X; Zhang S; Ma S; Qin C
J Med Chem; 2024 Feb; 67(4):2487-2511. PubMed ID: 38316747
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3Kα overcomes resistance to KRas
Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
[TBL] [Abstract][Full Text] [Related]
8. 143D, a novel selective KRAS
Xu LS; Zheng SX; Mei LH; Yang KX; Wang YF; Zhou Q; Kong XT; Zheng MY; Jiang HL; Xie CY
Acta Pharmacol Sin; 2023 Jul; 44(7):1475-1486. PubMed ID: 36725884
[TBL] [Abstract][Full Text] [Related]
9. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
10. Exploring Targeted Degradation Strategy for Oncogenic KRAS
Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
[TBL] [Abstract][Full Text] [Related]
12. Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.
Imaizumi T; Shimada I; Satake Y; Yamaki S; Koike T; Nigawara T; Kaneko O; Amano Y; Mori K; Yamanaka Y; Nakayama A; Nishizono Y; Shimazaki M; Nagashima T; Kuramoto K
Bioorg Med Chem; 2024 Jan; 98():117581. PubMed ID: 38176113
[TBL] [Abstract][Full Text] [Related]
13. Efficient targeted oncogenic KRAS
Yang F; Wen Y; Wang C; Zhou Y; Zhou Y; Zhang ZM; Liu T; Lu X
Eur J Med Chem; 2022 Feb; 230():114088. PubMed ID: 35007863
[TBL] [Abstract][Full Text] [Related]
14. D-1553: A novel KRAS
Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
[TBL] [Abstract][Full Text] [Related]
15. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer.
Bi K; Cheng J; He S; Fang Y; Huang M; Sheng C; Dong G
J Med Chem; 2023 Jan; 66(1):1048-1062. PubMed ID: 36563407
[TBL] [Abstract][Full Text] [Related]
17. Targeted Degradation of Oncogenic KRAS
Bond MJ; Chu L; Nalawansha DA; Li K; Crews CM
ACS Cent Sci; 2020 Aug; 6(8):1367-1375. PubMed ID: 32875077
[TBL] [Abstract][Full Text] [Related]
18. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
19. Cell Type-specific Adaptive Signaling Responses to KRAS
Solanki HS; Welsh EA; Fang B; Izumi V; Darville L; Stone B; Franzese R; Chavan S; Kinose F; Imbody D; Koomen JM; Rix U; Haura EB
Clin Cancer Res; 2021 May; 27(9):2533-2548. PubMed ID: 33619172
[TBL] [Abstract][Full Text] [Related]
20.
Tu G; Liu Q; Qiu Y; Leung EL; Yao X
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]